Insights

Gathering insights about Elevati…

Similar companies to Elevati

Elevati Tech Stack

Elevati uses 8 technology products and services including Gravatar, Amazon Web Services, Amazon ALB, and more. Explore Elevati's tech stack below.

Gravatar
Audio, Video, Graphics
Amazon Web Services
Cloud Hosting
Amazon ALB
Load Balancers
Google Maps
Maps
Bootstrap
UI Frameworks
ShareThis
Widgets
Google Plus
Widgets
Facebook
Widgets

Media & News

HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Elevation Oncology, Inc. (NASDAQ: ELEV) related to its sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Elevation shareholders will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing. Is it a fair deal?
Jun 15, 2025 | www.globenewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
NEW YORK , June 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Know Labs, Inc. (NYSE American: KNW)'s sale to Goldeneye 1995 LLC. If you are a Know Labs shareholder, click here to learn more about your legal rights and options.
Jun 12, 2025 | www.prnewswire.com
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Elevation Oncology, Inc. (NasdaqCM: ELEV) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Elevation will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in e.
Jun 10, 2025 | www.businesswire.com
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Elevation Oncology, Inc. (NASDAQ: ELEV) to Concentra Biosciences, LLC is fair to Elevation shareholders. Under the terms of the proposed transaction, Elevation shareholders will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds re.
Jun 09, 2025 | www.businesswire.com
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right
BOSTON , June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock ("Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing, each pursuant to the contingent value rights agreement (the "CVR Agreement"). The Elevation Oncology Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Elevation Oncology stockholders and has approved the Merger Agreement and related transactions.
Jun 09, 2025 | www.prnewswire.com
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
-- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 -- BOSTON , May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2025, and provided recent business updates. "We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, and supporting our goal of providing a safer and more effective option for patients with HER3-expressing solid tumors," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
May 15, 2025 | www.prnewswire.com
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
-- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON , April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, Illinois.
Apr 25, 2025 | www.prnewswire.com

Elevati's Email Address Formats

Elevati uses at least 1 format(s):

Elevati Email Formats	Example	Percentage
First@elevati.com	John@elevati.com	50%
First@elevati.com	John@elevati.com	50%

Frequently Asked Questions

Where is Elevati's headquarters located?

Elevati's main headquarters is located at 343 East 4th North, Suite #200. The company has employees across 3 continents, including North AmericaSouth AmericaAsia.

What is Elevati's phone number?

You can contact Elevati's main corporate office by phone at

+1-800-236-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Elevati's stock symbol?

Elevati is a publicly traded company; the company's stock symbol is ELEV.

What is Elevati's official website and social media links?

Elevati's official website is elevati.com and has social profiles on LinkedIn.

What is Elevati's SIC code NAICS code?

Elevati's SIC code is 7929 - Bands, Orchestras, Actors, and Other Entertainers and Entertainment Groups NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Elevati have currently?

As of December 2025, Elevati has approximately 11 employees across 3 continents, including North AmericaSouth AmericaAsia. Key team members include Owner: D. A.Client Relations Director: S. D.Advertising Operations Manager: C. P.. Explore Elevati's employee directory with LeadIQ.

What industry does Elevati belong to?

Elevati operates in the Technology, Information and Internet industry.

What technology does Elevati use?

Elevati's tech stack includes GravatarAmazon Web ServicesAmazon ALBGoogle MapsBootstrapShareThisGoogle PlusFacebook.

What is Elevati's email format?

Elevati's email format typically follows the pattern of First@elevati.com. Find more Elevati email formats with LeadIQ.

When was Elevati founded?

Elevati was founded in 2013.

Elevati

Q: What is Elevati's official website and social media links?

Elevati's official website is elevati.com. Elevati has social profiles on LinkedIn.

Q: How many employees does Elevati have currently?

Elevati has approximately 11 employees.

Q: What technology does Elevati use?

Elevati's tech stack includes WordPress, PHP, Trustpilot, Yoast SEO, Gravatar.

Technology, Information and InternetIdaho, United States11-50 Employees

Elevati is focused on social entrepreneurship.  We create digital ventures that make a profit and a difference for good in the world.  We currently focus on causes such as: adoption, fertility, pregnancy and foster care. Our first website, Adoption.com was founded in Provo Utah in 1997 and has since grown to be the world’s most-used adoption service (source: Alexa.com). Our headquarters are currently in Rexburg Idaho USA with one additional office in Pune India.

Company Overview

Headquarters: 343 East 4th North, Suite #200
Phone number: +1-800-236-****
Website: elevati.com
SIC Code: 7929 - Bands, Orchestras, Actors, and Other Entertainers and Entertainment Groups
Stock Symbol: ELEV
NAICS Code: 5415 - Computer Systems Design and Related Services
Founded: 2013
Employees: 11-50

Media & News

Funding & Financials

$1M$10M
Elevati's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$1M$10M
Elevati's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Elevati

GetResponse

Marketo

Salesforce

ActiveCampaign

HubSpot

Intuit Mailchimp

Pardot

Elevati Tech Stack

Media & News

HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV

ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders

Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Elevati's Email Address Formats

Frequently Asked Questions

Where is Elevati's headquarters located?

What is Elevati's phone number?

What is Elevati's stock symbol?

What is Elevati's official website and social media links?

What is Elevati's SIC code NAICS code?

How many employees does Elevati have currently?

What industry does Elevati belong to?

What technology does Elevati use?

What is Elevati's email format?

When was Elevati founded?

Elevati

Company Overview

Media & News

HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?